Pharma Bodies Advocate ‘One Molecule-One MRP’ Policy

New Delhi : Representatives of several small and medium-sized pharmaceutical companies have proposed that the government adopt a one-molecule-one-MRP formula instead of rationalizing the markup (TMR) for non-listed drugs to reduce their prices. They plan to discuss this during a meeting convened by union minister for health, chemicals and fertilizers Mansuh Mandavia with industry representatives on Tuesday. The government is preparing to apply the TMR formula to non-scheduled drugs.

As ET previously reported, the National Pharmaceutical Pricing Authority (NPPA), India’s price regulator, resumed discussions with stakeholders on the issue in May. The previous round of negotiations took place in November 2019. The trade margin is the difference between the price at which producers/importers sell goods to stockists and the price charged to consumers. The NPPA currently sets prices for drugs on the list. Prices for medicines not included in the list are allowed to increase by no more than 10% per year.

Tuesday’s meeting is likely to include Laghu Udyog Bharati, the Federation of Pharmaceutical Entrepreneurs, the Himachal Drug Manufacturers Association and the Generic Pharmaceutical Federation of India, among others.

“We are asking the government to find another way and apply a single formula for all segments,” said Rajesh Gupta, head of Laghu Udyog Bharati across India.

  • Related Posts

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy, the online medical platform emphasizes the importance of early prevention and regular health screenings to reduce the risk of diabetes. By encouraging individuals to undergo timely blood sugar tests,…

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    India’s pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    UP expands food, drug testing capacity across all 18 divisions

    UP expands food, drug testing capacity across all 18 divisions

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi